Enzalutamide for hormone-relapsed non-metastatic prostate cancer Technology appraisal guidance [TA580]

NICE |  May 2019 | Enzalutamide for hormone-relapsed non-metastatic prostate cancer Technology appraisal guidance [TA580]

Evidence-based recommendations on enzalutamide (Xtandi) for treating high-risk hormone-relapsed non-metastatic prostate cancer in adults.

Full details from NICE 

 

 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s